Piet Ost, MD, PhD
For patients with oligorecurrent prostate cancer, androgen deprivation therapy (ADT)–free survival was superior for those assigned to metastasis-directed therapy (MDT) versus surveillance, according to findings from a phase II trial published in the Journal of Clinical Oncology.
Following sPLND, investigators observed hypoesthesia of the genitofemoral nerve (n = 1), lymphorrhea (n = 1), and scrotal and penile edema (n = 1).
Ost P, Decaestecker K Fonteyne V, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial [published online December 14, 2017]. J Clin Oncol. doi: 10.1200/JCO.2017.75.4853.
... to read the full story